Stock Report

Download full stock data and analysis for free Last Updated: 30-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Suven Life Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: SUVEN | BSE: 530239

₹320.20

up-down-arrow ₹-4.55 (-1.40%)

As on 30-Sep-2026IST

Market cap

info icon

₹9,042 Cr

Revenue (TTM)

info icon

₹9 Cr

P/E Ratio

info icon

--

P/B Ratio

info icon

16.2

Div. Yield

info icon

0 %

Edit peer-selector-edit
Suven Life Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 9,042 36,727 27,650 16,942 14,349
Revenue (₹ Cr)
 9 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 -352.44 1,018.97 497.77 603.02 270.18
Net Margin (%)
 -1,187.94 10.47 20.72 22.63 23.29
RoE (%)
 -80.77 21.30 28.49 19.61 14.45
Price to Earnings
 -- 36.31 55.55 28.10 52.11
Price-To-Book
 16.24 7.02 13.68 4.86 6.92

Income Statement (₹ Cr)

Suven Life Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
8.81 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
29.67 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
375.07 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
-366.26 1,943.92 762.90 836.69 388.38
Depreciation arrow
6.40 425.10 98.11 78.88 74.78
EBIT arrow
-372.66 1,518.82 664.79 757.81 313.60
Interest arrow
0.63 148.45 26.33 5.43 0.26
Other Income arrow
20.85 47.39 30.80 73.83 51.50
Exceptional Items arrow
0.00 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
-352.44 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
0.00 370.94 171.48 197.53 91.39
Profit after Tax arrow
-352.44 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Suven Life Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
591.40 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.00 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
1.92 723.57 345.47 142.73 50.51
Current Liabilities arrow
30.90 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
624.21 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Suven Life Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
59.44 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
546.71 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
624.21 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
0.00 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
515.81 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
6.17 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Suven Life Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
-301.41 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
-462.11 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
756.78 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
-6.75 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Suven Life Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
-78.71 25.25 27.50 24.61 18.04
ROE (%) arrow
-80.77 21.30 28.49 19.61 14.45
ROA (%) arrow
-92.82 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
-4,228.02 15.68 28.03 29.25 28.29
Net Margin (%) arrow
-1,187.94 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Suven Life Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
17.25 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
-94.41 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
-91.31 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
-70.96 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
299.38 11.36 22.95 18.43 11.27

Valuation Ratios

 Suven Life Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
-22.04 35.65 55.02 27.22 51.72
Price / Book Value arrow
16.15 7.04 13.55 4.87 6.93
Dividend Yield (%) arrow
0.00 0.19 0.16 0.36 0.55
EV/EBITDA arrow
-23.14 19.48 35.69 19.33 35.93
Market Cap (₹ Cr) arrow
3,503.53 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Suven Life Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.00 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
-- 0.16 -- -- --
Current Ratio arrow
17.69 1.43 2.09 5.21 7.39
Quick Ratio arrow
17.69 0.82 1.37 3.85 5.46
Interest Coverage arrow
-554.90 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Suven Life Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
17.11 26.46 22.82 41.42 41.52
Asset Turnover arrow
0.02 1.09 0.93 0.70 0.52
Receivable days arrow
72.97 88.68 77.32 144.58 169.86
Inventory Days arrow
8.71 84.11 80.83 96.67 97.92
Payable days arrow
-- 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
-- -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...